PETMED EXPRESS Q4 FY26 earnings call PETS

Fiscal year 2026 was a pivotal year for PetMed Express, marked by significant financial, operational, and cultural improvements. The company stabilized its core business and strengthened its foundation in the second half of the year. Regulatory compliance was regained with the filing of the FY25 10-K and Q1/Q2 FY26 quarterly filings, and three previously disclosed material weaknesses were fully remediated.

While full-year net sales for FY26 were down 21.1% to $179 million, the company observed a slowing of year-over-year revenue decline in Q3 and Q4, with Q4 sales down 15.6% to $42.8 million. PetMed Express achieved its first sequential quarterly increase in net sales since FY24, indicating positive momentum. Green shoots were noted in prescription medication sales, food sales, and autoship sign-ups.

PetMed Express made meaningful progress on cost reduction efforts, including exiting underperforming vendor relationships that will yield approximately $6.1 million in annualized savings. The company strategically reorganized to optimize headcount productivity across its pharmacy, call center, and distribution centers. This led to a lower cost structure aligned with business size and improved customer-facing operational metrics.

Several important technology and infrastructure initiatives were completed, including the successful implementation of a new ERP system, a new fraud prevention system, and new call center technology. These implementations modernize the tech stack, significantly improve operations, and are critical for providing exceptional customer service. The company plans to continue prioritizing website and user experience optimization while reducing operational risk.

The company celebrated its 30th anniversary, recognizing over 40 employees with more than 10 years of service, half of whom will have 20+ years by year-end. PetMed Express reorganized its leadership structure, creating a Chief Growth Officer role and promoting key internal talent. Employee benefits coverage was expanded, resulting in substantially increased employee satisfaction ratings due to a renewed focus on culture.

Looking ahead, PetMed Express plans to build on its foundation by focusing on improved customer retention through operational and technology enhancements. The company also aims to expand its market footprint through B2B relationships, membership programs, and white-label pharmacy fulfillment services. A Master Services Agreement with Rural King was announced as an example of leveraging pharmacy expertise and infrastructure to reach more customers.

In December 2025, the company received two unsolicited nonbinding preliminary proposals to acquire all outstanding common stock at prices ranging from $4 to $4.25 per share. After careful evaluation with financial and legal advisers, and soliciting interest from other potential sponsors, the Board determined it was in the best interest of the company and stockholders not to proceed. PetMeds will continue as an independent public company, though the Board remains open to future inbound indications of interest.